{"entity":{"id":"bmasgpk-austria","kind":"institution","name":"Federal Ministry of Labour, Social Affairs, Health, Care and Consumer Protection, Austria","aka":["BMASGPK","Sozialministerium","Bundesministerium für Arbeit, Soziales, Gesundheit, Pflege und Konsumentenschutz","Austrian Ministry of Health"],"tldr":"Austria's health ministry. It publishes the National Cancer Framework Programme 2026 to 2035, hosts the oncology advisory board and the national board that assesses costly hospital medicines, and oversees the medicines authority.","summary":"The ministry published Austria's first National Cancer Framework Programme in 2014 and a second for 2026 to 2035, an expert paper written under its oncology advisory board (a commission under the Federal Ministries Act) that sets goals, measures and indicators from prevention to palliative care but deliberately names no responsibilities or milestones. The programme credits the first round with the National Screening Committee for Cancer founded in 2021, a model rulebook for tumour boards in 2015, a national information point on cancer trials in 2017 and digital-only reporting to the national cancer registry from 2019.\n\nThe ministry hosts the Bewertungsboard set up under section 62d of the federal Hospitals Act after the 2023 health reform, which first met on 11 September 2024 and recommends whether and how selected high-priced medicines should be used in hospitals; its cancer decisions include a conditional recommendation for tisotumab vedotin in cervical cancer (24 June 2026) and no recommendation for obe-cel in adults with relapsed B-cell leukaemia (19 November 2025). Statistik Austria produced the cancer forecast to 2045 on the ministry's behalf, and the medicines authority BASG is an authority under the ministry.","asOf":"2026-11-11","links":[{"label":"BMASGPK: Nationales Krebsrahmenprogramm","url":"https://www.sozialministerium.gv.at/Themen/Gesundheit/Nicht-uebertragbare-Krankheiten/Krebs/Nationales-Krebsrahmenprogramm.html"},{"label":"Nationales Krebsrahmenprogramm 2026 bis 2035 (PDF)","url":"https://broschuerenservice.sozialministerium.gv.at/Home/Download?publicationId=929&attachmentName=Nationales_Krebsrahmenprogramm_2026_bis_2035.pdf"},{"label":"BMASGPK: Bewertungsboard für ausgewählte Arzneimittel","url":"https://www.sozialministerium.gv.at/Themen/Gesundheit/Gesundheitssystem/Bewertungsboard.html"}],"tags":[],"related":[],"cancers":["cervical","breast-cancer","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["tisotumab-vedotin","obecabtagene-autoleucel","lifileucel"],"companies":[],"institutions":["statistik-austria-cancer-registry","basg-austria","dachverband-sozialversicherung","oegk-austria","oesterreichische-krebshilfe"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-oberaigner-tyrol-mammography-advanced-breast-cancer-2017","paper-geiger-gritsch-tyrol-mammography-ultrasound-2018","paper-waser-hpv-vaccination-parents-tyrol-2022"],"journals":[],"dependsOn":[],"notes":[],"city":"Vienna","country":"AT","lat":48.208,"lng":16.373,"institutionType":"government","website":"https://www.sozialministerium.gv.at","programs":["National Cancer Framework Programme 2026 to 2035","Oncology advisory board (Onkologiebeirat)","Bewertungsboard for selected high-priced hospital medicines","National Screening Committee for Cancer (2021)","Model rulebook for tumour boards"]},"route":"/institutions/bmasgpk-austria/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/"},{"id":"obecabtagene-autoleucel","kind":"drug","name":"Obecabtagene autoleucel","route":"/drugs/obecabtagene-autoleucel/"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/"}],"institution":[{"id":"oesterreichische-krebshilfe","kind":"institution","name":"Austrian Cancer Aid (Österreichische Krebshilfe)","route":"/institutions/oesterreichische-krebshilfe/"},{"id":"oegk-austria","kind":"institution","name":"Austrian Health Insurance Fund (Österreichische Gesundheitskasse)","route":"/institutions/oegk-austria/"},{"id":"statistik-austria-cancer-registry","kind":"institution","name":"Austrian National Cancer Registry (Statistik Austria)","route":"/institutions/statistik-austria-cancer-registry/"},{"id":"basg-austria","kind":"institution","name":"Federal Office for Safety in Health Care (BASG) and AGES Medicines Market Surveillance","route":"/institutions/basg-austria/"},{"id":"dachverband-sozialversicherung","kind":"institution","name":"Federation of Austrian Social Insurance Institutions (Dachverband der Sozialversicherungsträger)","route":"/institutions/dachverband-sozialversicherung/"}],"paper":[{"id":"paper-oberaigner-tyrol-mammography-advanced-breast-cancer-2017","kind":"paper","name":"Fewer advanced breast cancers after organised mammography screening began in Tyrol, Austria","route":"/key-papers/paper-oberaigner-tyrol-mammography-advanced-breast-cancer-2017/"},{"id":"paper-geiger-gritsch-tyrol-mammography-ultrasound-2018","kind":"paper","name":"Four years of organised mammography screening combined with ultrasound in Tyrol, Austria","route":"/key-papers/paper-geiger-gritsch-tyrol-mammography-ultrasound-2018/"},{"id":"paper-waser-hpv-vaccination-parents-tyrol-2022","kind":"paper","name":"Parents' reasons for accepting or rejecting HPV vaccination for their children in Tyrol, Austria","route":"/key-papers/paper-waser-hpv-vaccination-parents-tyrol-2022/"}]}}